GemPharmatech Co., Ltd. (SHA:688046)

Market Cap	10.41B +104.6%
Revenue (ttm)	830.61M +18.6%
Net Income	159.76M +44.8%
EPS	0.40 +48.4%
Shares Out	408.97M
PE Ratio	63.52
Forward PE	55.35
Dividend	0.22 (0.86%)
Ex-Dividend Date	Jun 9, 2026

Volume	13,023,124
Open	23.99
Previous Close	24.23
Day's Range	23.60 - 26.17
52-Week Range	12.89 - 26.33
Beta	0.86
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About GemPharmatech

GemPharmatech Co., Ltd., a contract research organization, provides genetically engineered mouse models and preclinical research services to the scientific community worldwide. The company offers mouse models, including knockout and conditional knockout mouse, knock-in mouse, point-mutation mouse, transgenic mouse, immunodeficient mouse, germ-free mouse, and tool mice models, as well as operates wild mouse project. It also provides custom model generation, preclinical testing, germ-free and microbiome, cell lines and customization, custom breed...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 1,590
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688046

Financial Performance

In 2025, GemPharmatech's revenue was 793.39 million, an increase of 15.51% compared to the previous year's 686.84 million. Earnings were 142.64 million, an increase of 29.88%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jul 12, 2026

Data Sources Report a data error